Transgenic arthritic mice expressing a T-cell receptor transgene
US5675060A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | May 19, 1994 |
| Grant date | Oct 7, 1997 |
| Priority date | — |
| Expiry date | May 19, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0368
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A transgenic animal model for arthritis is disclosed. The arthritic condition results from genetic (or immunologic) manipulations that result in the T cell receptor (TCR) repertoire of the animal being substantially limited relative to the TCR repertoire of a wildtype control animal. The TCR repertoire of the arthritic animal, albeit limited, is functionally viable. In a preferred embodiment, the invention relates to transgenic arthritic mice wherein arthritis results from (1) a transgenic allele which encodes and expresses TCR .alpha. and .beta. subunits that combine in T lymphocytes of the transgenic animal to form a TCR that recognizes an antigen comprising one or more epitopes of an oligopeptide derived from amino acids 41-61 of bovine pancreatic ribonuclease and/or (2) polypeptide arthritogenic self antigens derived from endogenous proteins. The transgenic arthritic mice of the invention provides an animal model which faithfully mimics rheumatoid arthritis and by which human arthritogenic and therapeutic anti-arthritic compositions are evaluated. Also provided herein are therapeutic oligopeptides derived from the variable regions of the TCRs of the transgenes of the invention …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.